AGREE Guideline Evaluation

Each item assessed from 1-7, 1 being strongly disagree, 7 being strongly agree

Scope and Purpose /21 CPG-1 CPG-2 CPG-3 CPG-4 CPG-5 CPG-6 CPG-7

1. The overall objective(s) of the guideline is (are)

1-7
specifically described
7 5 7 7 7 7 7

2. The health question(s) covered by the guideline is (are)

1-7
specifically described
7 7 5 7 5 6 6

3. The population (patients, public, etc) to whom the

1-7
guideline is meant to apply are specifically described
7 7 5 7 5 6 7

Stakeholder involvement /21

4. The guideline development group includes individuals

1-7
from all the relevant professional groups
7 6 7 7 5 7 7
5. The views and preferences of the target population
1-7
(patients, public, etc.) have been sought.
7 6 5 7 6 6 7

6. The target users of the guideline are clearly defined 1-7

7 5 5 7 7 6 6

Rigour of development /56 CPG-1 CPG-2 CPG-3 CPG-4 CPG-5 CPG-6 CPG-7

7. Systematic methods were used to search for evidence 1-7

7 7 5 7 7 6 6

8. The criteria for selecting the evidence are clearly

1-7
described
7 5 6 7 6 5 7

9. The strengths and limitations of the body of evidence

1-7
are clearly described.
5 5 5 7 5 5 7

10. The methods used for formulating the

1-7
recommendations are clearly described
5 5 5 7 6 5 7
11. The health benefits, side effects and risks have been
1-7
considered in formulating the recommendations
6 4 6 7 5 5 6

12. There is an explicit link between the recommendations

1-7
and the supporting evidence
6 4 4 7 6 6 6

13. The guideline has been externally reviewed by experts

1-7
prior to its publication
5 6 6 7 6 6 6

14. A procedure for updating the guideline is provided 1-7

5 5 6 7 6 6 6

Clarity and Presentation /21 CPG-1 CPG-2 CPG-3 CPG-4 CPG-5 CPG-6 CPG-7

15. The recommendations are specific and unambiguous 1-7

6 6 7 7 6 6 6

16. The different options for management of the condition

1-7
or health issue are clearly presented

6 6 6 7 6 6 6
17. Key recommendations are easily identifiable 1-7

4 5 5 7 6 6 6

Applicability /28

18. The guideline describes facilitators and barriers to its

1-7
application
5 5 5 7 7 6 7

19. The guideline provides advice and/or tools on how the

1-7
recommendations can be put into practice.
6 6 6 6 7 6 7

20. The potential resource implications of applying the

1-7
recommendations have been considered
6 6 6 6 6 6 6

21. The guideline presents key monitoring and/or auditing

1-7
criteria
6 6 6 6 5 5 6

Editorial Independence /14 CPG-1 CPG-2 CPG-3 CPG-4 CPG-5 CPG-6 CPG-7
22. The views of the funding body have not influenced the
1-7
content of the guideline.
6 6 6 6 7 6 7

23. Competing interests of guideline development group

1-7
members have been recorded and addressed.
5 5 6 6 5 6 7

Would you recommend these

guidelines for use in practice?
yes yes yes yes yes yes yes
CPG-8 CPG-9 CPG-10 CPG-11 CPG-12 CPG-13

7 7 7 7 7 7

6 7 7 7 7 7

7 7 7 7 7 7

7 7 7 7 7 7
 7 7 7 7 7 7

7 7 7 7 7 7

CPG-8 CPG-9 CPG-10 CPG-11 CPG-12 CPG-13

7 7 7 6 7 7

7 7 7 5 7 5

7 7 7 5 7 5

7 7 7 6 7 5
 7 7 7 6 7 6

7 7 7 6 7 6

7 7 7 6 7 7

7 7 7 6 5 5

CPG-8 CPG-9 CPG-10 CPG-11 CPG-12 CPG-13

7 7 7 6 7 7

7 7 7 6 6 7
 7 7 7 7 7 7

7 7 7 6 7 7

7 7 7 6 7 7

7 7 7 6 7 7

7 7 7 6 7 7

CPG-8 CPG-9 CPG-10 CPG-11 CPG-12 CPG-13

 7 7 7 6 7 7

7 7 7 5 7 7

yes yes yes yes yes yes